间质性肺疾病急性加重期的肺移植治疗
该回顾性研究纳入2015至2018年因间质性肺疾病急性加重(AE-ILD)入院的53例患者,其中25例接受肺移植,28例仅药物治疗;同期67例稳定期ILD患者接受肺移植作为对照。结果显示AE-ILD移植患者全部存活至出院,而仅药物治疗者出院存活率仅43%;移植后1年生存率AE-ILD组与稳定ILD组无差异(96% vs 92.5%),原发性移植物功能障碍、移植后住院时间和急性细胞排斥反应率两组相似。结论提示对经选择的AE-ILD患者,肺移植可作为一种治疗选择。
要点
- AE-ILD移植患者全部存活至出院,仅药物治疗者出院存活率仅43%。
- AE-ILD组与稳定ILD组移植后1年生存率无差异(96% vs 92.5%)。
- 两组原发性移植物功能障碍、移植后住院时间和急性细胞排斥反应率相似。
核心结论
- AE-ILD期间接受肺移植的患者与稳定期ILD移植患者相比,总生存率、原发性移植物功能障碍率和急性排斥反应率无有意义的差异。
- 结果提示肺移植可考虑作为经选择的AE-ILD患者的治疗选择。
研究设计与样本
- 回顾性研究,纳入2015至2018年连续入住本机构的AE-ILD患者。
- AE-ILD入院患者53例,其中25例接受移植、28例仅药物治疗;同期稳定期ILD接受移植患者67例作为对照。
主要发现
- AE-ILD移植患者全部存活至出院,而仅药物治疗的AE-ILD患者出院存活率仅43%。
- 移植后1年生存率AE-ILD组为96%,稳定ILD组为92.5%,两组无差异。
- 两组原发性移植物功能障碍、移植后住院时间和急性细胞排斥反应率相似。
临床怎么用
- 对经选择的AE-ILD患者,可考虑将肺移植作为一种治疗选择。
局限性
- 本研究为单中心回顾性研究,样本量有限(AE-ILD移植25例,稳定ILD移植67例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute exacerbations of interstitial lung diseases (AE-ILD) have a high mortality rate with no effective medical therapies. Lung transplantation is a potentially life-saving option for patients with AE-ILD, but its role is not well established. The aim of this study is to determine if this therapy during AE-ILD significantly affects post-transplant outcomes in comparison to those transplanted with stable disease. METHODS: We conducted a retrospective study of consecutive patients with AE-ILD admitted to our institution from 2015 to 2018. The comparison group included patients with stable ILD listed for lung transplant during the same period. The primary end-points were in-hospital mortality for patients admitted with AE-ILD and 1-year survival for the transplanted patients. RESULTS: Of 53 patients admitted for AE-ILD, 28 were treated with medical therapy alone and 25 underwent transplantation. All patients with AE-ILD who underwent transplantation survived to hospital discharge, whereas only 43% of the AE-ILD medically treated did. During the same period, 67 patients with stable ILD underwent transplantation. Survival at 1 year for the transplanted patients was not different for the AE-ILD group versus stable ILD group (96% vs 92.5%). The rates of primary graft dysfunction, post-transplant hospital length-of-stay and acute cellular rejection were similar between the groups. CONCLUSION: Patients with ILD transplanted during AE-ILD had no meaningful difference in overall survival, rate of primary graft dysfunction or acute rejection compared with those transplanted with stable disease. Our results suggest that lung transplantation can be considered as a therapeutic option for selected patients with AE-ILD.
引用
- Chizinga M, Machuca TN, Shahmohammadi A, et al. Lung transplantation for acute exacerbation of interstitial lung disease. Thorax. 2021. PMID: 34226204. doi:10.1136/thoraxjnl-2020-215681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。